Advances of PD-1/PD-L1 inhibitors in the immunotherapy for urologic malignancies
Wang Hanfeng
Duan Junyao
Wu Shengpan
Chen Jianwen
Lei Zhenwei
Tang Lu
Abstract：Overexpression of immune checkpoint molecules suppresses tumor-specific T cell immunity in the cancer microenvironment, contributes to tumor immune escape and promotes tumor progression and metastasis.Programmed death-1 (PD-1) and its ligand (PD-L1) are two of immune checkpoint molecules that have been studied profoundly, and currently increasing clinical trials demonstrated that PD-1 and PD-L1 inhibitors turned out to be beneficial and safe for urologic malignancies.Here, we update the progression of PD-1/PD-L1 inhibitors in the treatment of urologic malignancies.
Keywords：programmed death-1programmed death-1 ligandurologic malignancyimmune therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 177-182 )